Sun Pharmaceutical Industries has launched Tedizolid Phosphate tablets 200 mg in India under the brand name ‘STARIZO’. STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India.
STARIZO (Tedizolid Phosphate) is a once-a-day oral treatment for six days compared to the current standard of care which has to be given twice daily for 10-14 days. STARIZO (Tedizolid Phosphate) has demonstrated activity against gram-positive organisms, including MRSA. STARIZO (Tedizolid) provides the advantage of reduced frequency and duration of drug administration. STARIZO (Tedizolid Phosphate) requires no dose adjustment in the elderly, patients with hepatic or renal impairment and patients on haemodialysis. Tedizolid Phosphate is sold in India under a licensing agreement with Merck Sharp & Dohme Singapore Trading PTE.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1854.15 |
Dr. Reddys Lab | 1350.75 |
Cipla | 1497.80 |
Lupin | 2357.65 |
Zydus Lifesciences | 1001.20 |
View more.. |